IpiNovyx Bio Closes on $10 Million Seed Financing Round to Advance Proprietary Platform
“New York-based IpiNovyx Bio announced the closing of a $10 million seed financing round. The financing was led by Viva BioInnovator (a Viva Biotech division) and included participation from Lilly, Opaleye Management, Orange Grove Bio, and Alexandria Venture Investments. Ipinovyx is developing a platform of best-in-class immunoproteasome modulating therapeutics for the treatment of autoimmune and inflammatory diseases. Proceeds from the financing will support the company’s continued advancement of its lead drug candidates toward first-in-human clinical studies, including submission of the company’s first investigational new drug (IND) application. “Orange Grove Bio is dedicated to partnering with world-class researchers to advance the most promising drug development technologies emerging from leading academic institutions. We believe that IpiNovyx’s scientific founders and their unique approach to developing best-in-class immunoproteasome inhibitors are the ideal fit for this model,” said Marc Appel, co-founder, and chief executive officer of IpiNovyx and chief executive officer of Orange Grove Bio. “This seed funding will enable the company to rapidly …”
Michigan BioSocial Upcoming Webinar for Pre-Clinical Biotech Development Opportunities
November 17, 2021
New Partnership Continues Pitt’s Turn Toward Commercializing Research
New Partnership Continues Pitt’s Turn Toward Commercializing Research The following excerpt was taken from Pittsburgh Post-Gazette — continue reading here. An Ohio drug investment and development firm is partnering with the University of Pittsburgh to commercialize therapies “An Ohio drug investment and development firm is partnering with the University of Pittsburgh to commercialize therapies targeting
June 23, 2022
Orange Grove Bio Appoints Key Leadership & New Academic Collaboration
The University of Pittsburgh and Orange Grove Bio Establish Partnership… The following excerpt was taken from Globe Newswire — continue reading here. Orange Grove Bio, a preclinical drug investment and development firm, today announced several key leadership appointments highlighted by its naming John C. Byrd, M.D. Orange Grove Bio, a preclinical drug investment and development
July 5, 2022
Einstein Hosts Inaugural Therapeutics Venture and Pitch Competition
Einstein Hosts Inaugural Therapeutics Venture and Pitch Competition The following excerpt was taken from Einsteinmed.edu — continue reading here. Scientists, venture investment firm leaders, and industry stakeholders gathered on Tuesday, June 7 to attend Albert Einstein College… June 27, 2022—(BRONX, NY)—Scientists, venture investment firm leaders, and industry stakeholders gathered on Tuesday, June 7 to attend
October 6, 2021
Eli Lilly-backed IpiNovyx Bio emerges with $10M for 2023 clinical entry
Eli Lilly-backed IpiNovyx Bio emerges with $10M for 2023 clinical entry We are excited to announce our portfolio company, Ipinovyxbio‘s, launch! The following was taken from Fierce Biotech–read it here or continue below! “With a focus on autoimmune and inflammatory diseases, IpiNovyx Bio closed a $10 million seed financing round” “Eli Lilly is among the
May 11, 2026
IpiNovyx Bio Awarded NIH Catalyze Award to Advance Novel Proteasome Therapeutic for Systemic Sclerosis-Associated Interstitial Lung Disease
Funding to Support Preclinical Development of First-in-Class Inhaled Therapy Targeting Lung Inflammation and Fibrosis Cincinnati, OH, May 11, 2026 — IpiNovyx Bio, a biotechnology company developing best-in-class proteasome modulating therapeutics, and launched by Orange Grove Bio, today announced it has been selected to receive support from the National Heart, Lung, and Blood Institute’s (NHLBI) Catalyze
January 31, 2024
Orange Grove Bio Sets Sights on Rapidly Emerging Middle East Biotech Ecosystem through New Academic Collaboration with Weizmann Institute of Science
Partnership represents firm’s second international collaboration and provides access to groundbreaking research taking place within world’s fifth largest pharmaceutical market The following excerpt was taken from GlobeNewswire – continue reading here. CINCINNATI, January 31, 2023 (GLOBE NEWSWIRE) – Orange Grove Bio, a drug investment and development firm, today announced that it has established a new
February 9, 2022
Leading Korean VC partners with USA’s Orange Grove
Orange Grove Bio, a USA-based pre-clinical drug investment and development firm, and SV Investment, a South Korea-based venture capital and private equity firm, today announced the establishment of a new partnership through which the companies will collaborate on jointly sourcing and developing novel therapeutics in the USA and Korea. As priority partners, the companies will cultivate the US and Korean biotech landscape through technology licensing and company creation in their respective geographic areas. Under terms of the partnership, SV Investment will leverage its relationships with biotech companies and academic institutions in Korea to identify licensing opportunities for promising early-stage research in the area of drug development. As part of the agreement, Marc Appel, chief executive of Orange Grove, will join SV Investment as a venture partner and will play a key role in evaluating the licensing opportunities that are identified at Korean biotech companies and universities. As appropriate, Orange Grove will work to license these technologies as a basis for life science company creation in the USA, with SV Investment serving as an early-stage investor in the companies.
November 10, 2023
Orange Grove Bio Subsidiary Awarded $2.05 Million SBIR Phase II Grant to Advance Development of Novel Platelet Preservation Technology
OGB Also Announces Key Appointments to Board of Senior Advisors and the Opening of New Headquarters The following excerpt was taken from GlobeNewswire – continue reading here. CINCINNATI, Sept. 28, 2023 (GLOBE NEWSWIRE) Orange Grove Bio (OGB), a drug investment and development firm, today announced that Preservation Bio, one of the firm’s majority-owned subsidiaries, has been
